Clinical Guideline Strategy
IP leveraged its Medical Affairs expertise and experience supporting more than 70 submissions to key oncology clinical practice guidelines to advocate for the inclusion of a test that predicts the benefit of therapy, resulting in broad and appropriate access for patients.
The Challenge
The client had launched a test to predict which patients are likely to benefit from the extension of therapy beyond 5 years.
The client needed to understand how to best position their test so that clinical guideline decision-makers would include their test as a recommendation within the guidelines, to increase utilization at Academic Medical Centers and Community Oncology Practices.
The IP Solution
IP developed a plan to identify how to best position the test within the guidelines and submit to the decision-making panel:
- IP worked with the client to evaluate their data and the current landscape across competitive products and write a compelling guideline submission
- Following the submission, IP supported the client to conduct research at the point of care to understand how additional data might impact the current guideline recommendations as well as utility across supportive care guidelines
The Results
The product was included within the clinical practice guidelines and remains the only test of its kind that is recognized by guidelines authorities.
